Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
αCD19 CAR-Tconv cells
- Development stage
- Preclinical
- Lead developer
- Riddell Centre for Cancer Immunotherapy
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intratumoral
01
Overview
αCD19 CAR-Tconv cells are conventional CD4+ and CD8+ T cells (Tconv) genetically modified to express a chimeric antigen receptor (CAR) specific for the CD19 antigen. These cells typically utilize a second-generation CAR construct containing a 4-1BB costimulatory domain. In neuro-oncology research, such as studies conducted at the University of Calgary, αCD19 CAR-Tconv cells are frequently employed as a negative control to evaluate the efficacy and safety of novel CAR-T platforms (e.g., CAR-DNT cells) targeting glioblastoma-associated antigens like CD276 (B7-H3). While CD19-targeted CAR-T therapies are clinically established for B-cell malignancies, in the context of solid tumor research, they serve as a benchmark for assessing CAR-mediated versus CAR-independent cytotoxicity and the risk of xenogeneic graft-versus-host disease (GvHD).
- Other names
- anti-CD19 CAR-Tconv cellsanti-CD-19 CAR-Tconv cellsanti-CD 19 CAR-Tconv cellsCD19 CAR-Tconv cellsCD-19 CAR-Tconv cellsCD 19 CAR-Tconv cells
02
Targets
Beyond the preview
Go deeper on αCD19 CAR-Tconv cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on αCD19 CAR-Tconv cells.